Edition:
United Kingdom

Knight Therapeutics Inc (GUD.TO)

GUD.TO on Toronto Stock Exchange

8.13CAD
22 Jan 2019
Change (% chg)

-- (--)
Prev Close
$8.13
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
153,941
52-wk High
$8.81
52-wk Low
$7.38

Latest Key Developments (Source: Significant Developments)

Puma Biotechnology To Receive Payments Up To $7.2 Mln From License Agreement With Knight Therapeutics
Friday, 11 Jan 2019 

Jan 11 (Reuters) - Puma Biotechnology Inc::PUMA BIOTECHNOLOGY AND KNIGHT THERAPEUTICS ENTER INTO EXCLUSIVE LICENSE AGREEMENT TO COMMERCIALIZE NERLYNX® (NERATINIB) IN CANADA.PUMA BIOTECHNOLOGY INC - PUMA WILL RECEIVE UPFRONT AND MILESTONE PAYMENTS UP TO $7.2 MILLION USD THROUGHOUT TERM OF THIS AGREEMENT.PUMA BIOTECHNOLOGY INC - KNIGHT WILL BE RESPONSIBLE FOR ALL COMMERCIAL ACTIVITIES AND FUTURE REGULATORY SUBMISSIONS FOR NERLYNX IN CANADA.  Full Article

Knight Therapeutics Enters License Agreement With Puma Biotechnology To Commercialize Nerlynx In Canada
Friday, 11 Jan 2019 

Jan 11 (Reuters) - Knight Therapeutics Inc ::KNIGHT THERAPEUTICS INC - ENTERED INTO LICENSE AGREEMENT WITH PUMA BIOTECHNOLOGY GRANTING CO EXCLUSIVE RIGHT TO COMMERCIALIZE NERLYNX IN CANADA.  Full Article

Knight Therapeutics And Jaguar Health Announce Strategic Partnership
Monday, 24 Sep 2018 

Sept 24 (Reuters) - Knight Therapeutics Inc ::KNIGHT THERAPEUTICS AND JAGUAR HEALTH ANNOUNCE STRATEGIC PARTNERSHIP.KNIGHT THERAPEUTICS INC - TO BE RESPONSIBLE FOR ALL REGULATORY AND COMMERCIAL ACTIVITIES FOR MYTESI AND RELATED PRODUCTS IN LICENSED TERRITORIES.KNIGHT THERAPEUTICS - UPON ACHIEVEMENT OF REGULATORY, SALES MILESTONES IN AGREEMENT, JAGUAR TO RECEIVE PAYMENTS FROM CO OF UP TO $18.0 MILLION.KNIGHT THERAPEUTICS - AGREEMENT GRANTS CO EXCLUSIVE RIGHT TO COMMERCIALIZE MYTESI AND RELATED PRODUCTS IN CANADA AND ISRAEL.KNIGHT THERAPEUTICS INC - AGREEMENT GRANTS CO A RIGHT OF FIRST NEGOTIATION TO COMMERCIALIZE MYTESI & RELATED PRODUCTS IN SPECIFIED LATAM COUNTRIES.KNIGHT THERAPEUTICS INC - JAGUAR IS ALSO PURSUING POSSIBLE FOLLOW-ON INDICATIONS FOR MYTESI IN CANCER THERAPY-RELATED DIARRHEA.KNIGHT THERAPEUTICS - JAGUAR TO RECEIVE PAYMENTS FROM CO OF UP TO $18.0 MILLION THROUGHOUT INITIAL 15-YEAR TERM OF AGREEMENT.  Full Article

Knight Therapeutics Reports Q2 Basic EPS $0.028
Thursday, 9 Aug 2018 

Aug 9 (Reuters) - Knight Therapeutics Inc ::KNIGHT THERAPEUTICS REPORTS SECOND QUARTER 2018 RESULTS.QTRLY BASIC EARNINGS PER SHARE $ 0.028.QTRLY REVENUES $2.2 MILLION, DOWN 10 PERCENT.  Full Article

Knight Therapeutics And TherapeuticsMD Announce Strategic Partnership
Tuesday, 31 Jul 2018 

July 31 (Reuters) - Knight Therapeutics Inc ::KNIGHT THERAPEUTICS AND THERAPEUTICSMD ANNOUNCE STRATEGIC PARTNERSHIP.KNIGHT THERAPEUTICS - CO, THERAPEUTICSMD ENTERED LICENSING AGREEMENT THAT GRANTS CO RIGHTS TO COMMERCIALIZE TX-004HR AND TX-001HR IN CANADA AND ISRAEL.KNIGHT THERAPEUTICS INC - WILL PAY THERAPEUTICSMD A MILESTONE FEE UPON FIRST REGULATORY APPROVAL IN CANADA OF EACH OF TX-004HR AND TX-001HR.KNIGHT THERAPEUTICS - AGREED TO INVEST $20 MILLION IN THERAPEUTICSMD COMMON STOCK ALONG WITH CLOSING OF PUBLIC OFFERING OF THERAPEUTICSMD COMMON STOCK.  Full Article

KNIGHT THERAPEUTICS REPORTS Q3 EARNINGS PER SHARE $0.03
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Knight Therapeutics Inc :KNIGHT REPORTS THIRD QUARTER 2017 RESULTS.QTRLY ‍REVENUE $1.9 MILLION, A DECREASE OF 2 PERCENT​.QTRLY EARNINGS PER SHARE $0.03‍​.‍ALL CURRENCIES ARE CANADIAN​.  Full Article

Knight Therapeutics reports qtrly earnings per share $0.03‍​
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Knight Therapeutics Inc ::Knight reports third quarter 2017 results.Qtrly earnings per share $0.03.Q3 earnings per share view C$0.03 -- Thomson Reuters I/B/E/S‍​.Qtrly ‍revenues were $1.9 million, a decrease of 2 percent versus same period in prior year​.All currencies are Canadian‍​.  Full Article

Knight Therapeutics CFO Jeffrey Kadanoff steps down
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - Knight Therapeutics Inc :Jeffrey Kadanoff, CFO is leaving Knight effective October 13, 2017​.Effective immediately, Samira Sakhia, president of Knight, will assume additional responsibility of CFO​.  Full Article

Knight Therapeutics announces increase in ownership of Crescita Therapeutics
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - Knight Therapeutics Inc :Knight Therapeutics - ‍pursuant to early warning requirements of national instrument 62-103, co announced increase in ownership of Crescita Therapeutics.Knight Therapeutics Inc - ‍now owns aggregate of 2.08 million common shares of crescita representing about 14.9 pct of outstanding common shares of Crescita​.  Full Article